[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@pick1998_2 Avatar @pick1998_2 Nick zheng

Nick zheng posts on X about $janx, $fulc, pill, $capr the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks

Social topic influence $janx #31, $fulc #11, pill #280, $capr #25, $akro, $etnb, $inbx #5, hot, $1b, market cap

Top accounts mentioned or mentioned by @fireworkstrades @jfais20 @stmkrs @hothomaswphelps @aaronrosenblum5 @rnaianalyst @anonym64382296 @jmaraganore @tommygentiletti @mysteriousmole1 @biotechanalysst @bowtiedbiotech @jul05310473john @bioclouseau @mattnachtrab @respekchemistry @pick19982 @elitedaytraders @bymadeleinea @evaluatevantage

Top assets mentioned Janux Therapeutics, Inc. Common Stock (JANX) Akropolis (AKRO) Intellia Therapeutics, Inc (NTLA) Regeneron Pharmaceuticals Inc (REGN) Sarepta Therapeutics, Inc. (SRPT) Viking Therapeutics, Inc (VKTX) Eli Lilly and Company (LLY)

Top Social Posts

Top posts by engagements in the last XX hours

"$JANX until today no competitors have done better in treating advanced prostate cancer. For other solid cancers data are still lacking. Only worth 2B How about 5-10B at today's hot M&A market"
X Link 2025-10-28T14:07Z 7709 followers, 3655 engagements

"$JANX has $1B cash by end of 2nd quarter. market cap is under 2B even after considerable run-up from XX to XX from Fri. Very undervalued considering its T-cell engager platforms"
X Link 2025-10-28T16:48Z 7710 followers, 2150 engagements

"$NTLA $REGN Today's news about $REGN and Tessera collaborate on in-vivo gene editing for Alpha-1 antitrypsin deficiency (AATD) is another encouraging piece that in-vivo gene editing is the future for genetic diseases.$REGN often targets well for the future growth.Good for $NTLA"
X Link 2025-12-01T20:44Z 7711 followers, 1409 engagements

"$FULC good conference call with detailed data. It looks to me there are no questions about the efficacy of Pociredir to induce HbF to reduce VOC. It is oral pill a big advantage over gene therapy in market penetration. I guess attentions will slowly shift to long-term safety"
X Link 2025-12-07T13:00Z 7711 followers, 1872 engagements

"$FULC Last Friday there were lots of buy orders for X put options. They may end up worthless. Either longs were nervous or shorts were drooling (or both :-). Again stock/option trading before key data is often misleading. (but $CAPR surging before data must because of leaking)"
X Link 2025-12-07T13:09Z 7711 followers, 1628 engagements

"$AKRO $ETNB one of them will be very likely acquired this year. I believe $ETNB has more upward potential"
X Link 2025-05-27T16:55Z 7711 followers, 1929 engagements

"$AKRO $ETNB big loading-up at closing and they are still going up after hour. very encouraging that some positive news are brewing"
X Link 2025-06-13T21:15Z 7711 followers, 1565 engagements

"$JANX is going to update trial this quarter. It has best clinical data for metastatic/advanced prostate cancer. Huge market unmet need. Hope this babe holds the promise. Additional surprise for other solid cancers will be validation of its superior masked T-cell engagers"
X Link 2025-11-14T16:48Z 7709 followers, 15.3K engagements

"@AaronRosenblum5 they may have overcome toxicity issues of DR5 and it is expandable to other cancers. I expect supplemental applications following first approval. A platform is worth billions. $INBX"
X Link 2025-12-01T18:35Z 7711 followers, XXX engagements

"$CAPR cell therapy slows down the weakening of upper limb strength by half. It will help esp. non-ambulatory DMD boys. But I believe targeted therapies by $SRPT are more promising. We need to halt or reverse the disease progress. Non-targeted therapies will NOT do"
X Link 2025-12-03T14:44Z 7709 followers, 5181 engagements

"$JANX doubled my position by adding at 16s. Is the prostate cancer data so bad We will see better picture when phase Ib (chemo-naive and CRS-mitigation stategy CRS-P2) data are out next year. I am stuck with a long position averaged down to 22"
X Link 2025-12-03T15:42Z 7711 followers, 1499 engagements

"$INBX XX amazingly runs well. Not too late to buy at 40s after positive data were released. Keep it long until it is acquired. They have pretty Unique drugs among years of failures. My conviction: Biotech is hard to die; Phoenix arises from ash"
X Link 2025-12-04T15:47Z 7711 followers, 1233 engagements

"$FULC good data. 20mg is clearly more effective than 12mg. If long term safety is OK and VOC frequency continues to go down this oral pill will serve SCD pts very well"
X Link 2025-12-07T01:15Z 7710 followers, 1926 engagements

"$GPCR $VKTX $LLY Chinese competitor Ascletis Pharma Inc. showed promising oral pill for obesity. PR: it claims less GI side effects. Bloomberg report:"
X Link 2025-12-09T04:58Z 7711 followers, 1312 engagements